Loading…
← CockpitCompetitor Analysis › MCK McKesson CorporationOpen in the cockpit ↗

McKesson CorporationMCKCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Distributors

Largest US pharmaceutical distributor, delivering drugs and medical-surgical supplies to pharmacies, hospitals and providers, plus oncology platforms.

Momentum leader 94
Mkt cap
$125B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$740M
20-day average traded
Fwd P/E
22.1×
forward earnings
ROIC−WACC
+80.3 pp
WACC 6.5%
Hurdle
-17 pp
Req g minus delivered
Official | Implied
BBB+ / A
agencies · bond market
Next earnings
84 days
10 Feb 2027
Close · USD$1,084
1D-0.7%
1W+0.4%
1M+5.3%
3M+29.3%
6M+43.7%
YTD+32.3%
1Y+27.0%
ATR %2.3%
Beta-0.15
52w lowhigh3.3% off high

What McKesson does

Largest US pharmaceutical distributor, delivering drugs and medical-surgical supplies to pharmacies, hospitals and providers, plus oncology platforms.

Buys drugs from manufacturers and sells them to pharmacies and hospitals at a small markup on huge volume, with generic-drug contracts helping the margin. It also runs oncology practices through the US Oncology Network and sells medical-surgical supplies. It is one of three big US drug wholesalers, with Cencora and Cardinal.

Products and services

  • US Pharmaceutical distribution
  • Medical-Surgical distribution
  • Oncology/specialty platforms (US Oncology Network)
  • International (Canada) distribution

Customers

  • Retail/independent pharmacies
  • Hospitals
  • Physician practices
  • Specialty/oncology clinics

Where it sits in the supply chain

  • Healthcare
  • Pharmaceutical/medical distribution
  • Wholesale drug distribution

What could go right

  • Specialty drug volume growth
  • Oncology practice-management expansion

What could go wrong

  • Thin distribution margins/pricing pressure
  • Opioid litigation liabilities

Moat: narrow (scale, distribution, switching costs). Massive logistics scale and entrenched distribution contracts across the US drug supply chain.

Headquarters: Irving, Texas, USA · Founded: 1833 · Employees: 43,000

Named competitors

McKesson at a glance

Size McKesson (MCK) is a United States Health Care company (Medical Distributors) with a market value of $125B, the 97th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1,084 on 18 Nov 2026.

Performance Over six months the shares gained 43.7%, against +11.7% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 8.2% over the last twelve months (peer median +6.2%); the operating margin is 1.7% (peer median 2.9%).

Valuation It trades at 22.1× forward earnings against a peer median of 17.0× (4th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -17 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 80.3 points above its cost of capital (6.5% WACC).

Credit McKesson has 10 bonds outstanding ($4.89B), rated BBB+ by the agencies and trading like A at a weighted spread of 64 bp.

Short interest Short interest is 1.7% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026MCK 141Peer median 112
Six months, rebased to 100: McKesson against the median of its 20 peers (local-currency closes).

McKesson financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$419B$403B$359B$309B$277B
Revenue growth—+12%+16%+12%—
Gross profit$14.6B$14.1B$12.5B$12.2B$11.9B
EBITDA$7.87B$6.68B$5.01B$4.56B$5.31B
Net income$4.70B$4.76B$3.29B$3.00B$3.56B
Free cash flow$7.11B$5.72B$5.55B$3.88B$4.77B
Capital expenditure$635M$745M$859M$687M$558M
Total debt$11.2B$8.61B$7.39B$7.39B$7.29B

Quarterly statements and history in the cockpit →

McKesson competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%CORCAHHSIC1099DKSHGALE6009987459AMP33492784ASKER00893099878129RDC33606005877476DOCMMCK6-month return →1-month return →
Up and to the right = strong over both horizons. McKesson is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%10×20×CORCAHHSIC1099DKSHGALE6009987459AMP33492784ASKER9987812933606005877476MCKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. McKesson is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%CORCAHHSIC1099DKSHGALE6009987459AMPASKER00893099873360MCKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. McKesson is the large dot.

McKesson competitors and peer comparison

Head to head with its named competitors (MCK vs COR vs CAH vs CVS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
McKesson MCK$125B+44%+8%2%22.1×-5.5%
Cencora COR$66.5B+32%+5%1%17.7×-1.2%
Cardinal Health CAH$64.3B+40%+10%1%21.1×7.8%
CVS Health CVS$104B-13%+7%4%9.6×-3.8%

How McKesson compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

McKesson against its 20 peers (data as of 18 Nov 2026)
MeasureMCKPeer medianRank in peer set
1-month return+5.3%+1.8%6th highest of 21
6-month return+43.7%+11.7%4th highest of 21
Distance from 52-week high-3.3%-13.2%3rd highest of 21
Revenue growth (TTM)+8.2%+6.2%8th highest of 21
Operating margin1.7%2.9%9th lowest of 21
Forward P/E22.1×17.0×4th most expensive of 18
Growth the price implies (Req g, 7 yrs)-5.5%-1.2%7th least demanding of 18
Growth delivered (Del g)+11.1%+5.4%2nd highest of 18
Hurdle (Req g minus delivered)-16.6 pp-8.0 pp2nd least demanding of 18
ROIC minus cost of capital+80.3 pp+1.6 pphighest of 20
Net debt / EBITDA0.6×0.8×8th least indebted of 18
Bond spread64 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
McKesson MCKUnited States$125B+44%+8%2%22.1×-5.5%+11.1%
Cencora CORUnited States$66.5B+32%+5%1%17.7×-1.2%+9.5%
Cardinal Health CAHUnited States$64.3B+40%+10%1%21.1×7.8%+9.4%
Henry Schein HSICUnited States$9.47B+17%+6%6%14.7×10.2%+5.4%
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%6.2×-7.3%+4.0%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%21.8×-1.2%+0.6%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%23.9×7.0%+3.5%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a

McKesson bonds and credit

McKesson has 10 bonds outstanding with $4.89B face value. The agencies rate it BBB+; its bonds trade like A. Weighted yield 5.36%, a spread of 64 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are McKesson's main competitors?
Named competitors: Cencora (COR), Cardinal Health (CAH), CVS Health (CVS). The cockpit's measured peer set (industry) also includes Cencora (COR), Cardinal Health (CAH), Henry Schein (HSIC), Sinopharm (1099.HK), DKSH (DKSH.SW), Galenica (GALE.SW).
Is McKesson expensive compared with its peers?
On forward p/e it trades at 22.1× against a peer median of 17.0×, 4th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -17 pp: the price already allows for a slowdown.
How has McKesson stock performed?
Over six months to 18 Nov 2026 the shares returned +43.7% against +11.7% for the median peer; over one year +27.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.